Myelodysplastic Syndromes

Front Matter....Pages I-XV
Front Matter....Pages 1-1
The Classification of Myelodysplastic Syndromes....Pages 3-10
Discussion....Pages 11-14
Classification of Myelodysplastic Syndromes in Clinical Practice: Frequency of Subtypes....Pages 15-19
Pathogenesis of Anaemia in the Myelodysplastic Syndrome....Pages 20-24
Immunological Abnormalities in the Myelodysplastic Syndrome....Pages 25-30
Pediatric Experiences in Myelodysplastic Syndrome....Pages 31-37
Myelodysplastic Syndromes in Childhood: Description of 11 Cases....Pages 38-43
The Value of Cytochemical Investigations in the Diagnosis of the Myelodysplastic Syndrome*....Pages 44-50
Enzyme Cytochemical Studies in Myelodysplastic Syndromes....Pages 51-59
Immunological Phenotyping of Blood and Bone Marrow Cells From Patients with Myelodysplastic Syndromes....Pages 60-66
Bone Marrow Biopsy in RAEB and RAEB-t Myelodysplastic Syndromes....Pages 67-73
Discussion of Poster Session I....Pages 74-77
Front Matter....Pages 79-79
Maturation Pattern and Evolution of Leukemia in the Myelodysplastic Syndrome....Pages 81-89
Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia....Pages 90-98
The Prognostic Value of Abnormal Localization of Immature Precursors in the Myelodysplastic Syndromes....Pages 99-102
Bone Marrow Histology in Myelodysplastic Syndromes: An Update....Pages 103-106
Evolution of Myelodysplastic Syndromes....Pages 107-113
Conversion of Myelodysplastic Subtypes to Acute Leukemia: A Follow-Up Study....Pages 114-120
Primary Myelodysplastic Syndromes and Chronic Myelofibrosis....Pages 121-124
Myelodysplastic Syndrome with Myelofibrosis: A Report of Seven Cases....Pages 125-127
Front Matter....Pages 129-129
Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia....Pages 131-139
Chronic Myelomonocytic Leukemia with Lymphadenopathy....Pages 140-145
Generalized Lymphadenopathy in Juvenile Chronic Myelomonocytic Leukemia Is Due to Lymph Node Infiltration with Myelomonocytic Cells and Immature T Cells....Pages 146-154
Impaired Monocyte/Macrophage Differentiation in the Myelodysplastic Syndromes....Pages 155-158
Discussion of Poster Session II....Pages 159-161
Front Matter....Pages 163-163
Myelodysplastic Syndromes: Cytogenetic Anomalies and Their Clinical Significance....Pages 165-177
Genetic Consequences of Chromosomal Abnormalities in the Myelodysplastic Syndromes....Pages 178-186
ras Mutations in the Myelodysplastic Syndromes....Pages 187-192
Study of the Rearrangement of Proto-oncogene MET in 88 Cases of Myelodysplastic Syndromes....Pages 193-197
Front Matter....Pages 199-199
ras Oncogenes in Myelodysplastic Syndromes....Pages 201-214
Growth Factors in Myelodysplastic Syndromes....Pages 215-221
In Vitro Granulopoiesis in Myelodysplastic Syndromes According to the FAB Classification....Pages 222-232
Front Matter....Pages 233-233
Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors....Pages 235-239
Supportive Therapy and Bone Marrow Transplantation in MDS....Pages 240-247
Retinoic Acid Therapy in the Myelodysplastic Syndrome....Pages 248-252
Phase III Evaluation of Low-Dose Cytosine Arabinoside Versus Supportive Care in the Treatment of Adults With Myelodysplastic Syndrome: An Intergroup Study by the Eastern Cooperative Oncology Group and the Southwest Oncology Group—Preliminary Results....Pages 253-258
Intensive Chemotherapy in Myelodysplastic Syndromes....Pages 259-262
Therapeutic Effects of Low-Dose Cytosine Arabinoside Without or With 1,25-Dihydroxyvitamin D 3 in Myelodysplastic Syndromes and in Elderly Acute Nonlymphocytic Leukemia....Pages 263-267
Low-Dose Cytosine Arabinoside Regimen Adapted to the FAB Classifications of Myelodysplastic Syndromes: Is it Superior to Uniform Treatment for all Types of MDS?....Pages 268-273
Results of Low-Dose Cytosine Arabinoside and Aggressive Chemotherapy in Patients with Advanced Myelodysplastic Syndromes....Pages 274-281
Front Matter....Pages 233-233
Aggressive Chemotherapy in Adult Primary Myelodysplastic Syndromes: A Report on 29 Cases....Pages 282-288
Front Matter....Pages 289-289
Recombitant α 2b -Interferon in the Management of Myelodysplastic Syndromes....Pages 291-293
A Phase II Clinical Trial of Recombinant Interferon-γ on Myelodysplastic Syndromes....Pages 294-299
Treatment of Patients with Myelodysplastic Syndromes with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor: A Phase I/II Trial....Pages 300-314
Combined Treatment Modality with Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside in Patients with Myelodysplastic Syndromes....Pages 315-320
GM-CSF Combined with Low-Dose Cytosine Arabinoside: A Trial Proposed for High-Risk Myelodysplastic Syndromes and Results of a Dose-Finding Study....Pages 321-329
Discussion of Poster Session III....Pages 330-332
Back Matter....Pages 333-336